Hirshfeld surface analysis of sulfameter (polymorph III), sulfameter dioxane monosolvate and sulfameter tetrahydrofuran monosolvate,all at 296 K

The ability of the antibacterial agent sulfameter (SMT) to form solvates is investigated. The X‐ray crystal structures of sulfameter solvates have been determined to be conformational polymorphs. Both 1,4‐dioxane and tetrahydrofuran form solvates with sulfameter in a 1:1 molar ratio. 4‐Amino‐N‐(5‐methoxypyrimidin‐2‐yl)benzenesulfonamide (polymorph III), C₁₁H₁₂N₄O₃S, (1), has two molecules of sulfameter in the asymmetric unit cell. 4‐Amino‐N‐(5‐methoxypyrimidin‐2‐yl)benzenesulfonamide 1,4‐dioxane monosolvate, C₁₁H₁₂N₄O₃S·C₄H₈O₂, (2), and 4‐amino‐N‐(5‐methoxypyrimidin‐2‐yl)benzenesulfonamide tetrahydrofuran monosolvate, C₁₁H₁₂N₄O₃S·C₄H₈O, (3), crystallize in the imide form. Hirshfeld surface analyses and fingerprint analyses were performed to study the nature of the interactions and their quantitative contributions towards the crystal packing. Finally, Hirshfeld surfaces, fingerprint plots and structural overlays were employed for a comparison of the two independent molecules in the asymmetric unit of (1), and also for a comparison of (2) and (3) in the monoclinic crystal system. A three‐dimensional hydrogen‐bonding network exists in all three structures, involving one of the sulfone O atoms and the aniline N atom. All three structures are stabilized by strong intermolecular N—H...N interactions. The tetrahydrofuran solvent molecule also takes part in forming significant intermolecular C—H...O interactions in the crystal structure of (3), contributing to the stability of the crystal packing.     

A 2:1 sulfamethazine–theophylline cocrystal exhibiting two tautomers of sulfamethazine

In the title cocrystal, 4‐amino‐N‐(4,6‐dimethylpyrimidin‐2‐yl)benzenesulfonamide–4‐amino‐N‐(4,6‐dimethyl‐1,2‐dihydropyrimidin‐2‐ylidene)benzenesulfonamide–1,3‐dimethyl‐7H‐purine‐2,6‐dione (1/1/1), C₇H₈N₄O₂·2C₁₂H₁₄N₄O₂S, two sulfamethazine molecules cocrystallize with a single molecule of theophylline. Each molecule of sulfamethazine forms a hydrogen‐bonded ribbon along the b axis crosslinked by further hydrogen bonding. The two sulfamethazine molecules exhibit a hydrogen‐shift isomerization so that the crystal structure contains both tautomeric forms. Calculation of their relative energies showed that the tautomer protonated at the chain N atom is considerably more stable than the one where an N atom in the aromatic ring is protonated. The latter, here observed for the first time, is stabilized through strong intermolecular interactions with the theophylline molecules.     

3‐Cyano‐6‐hydroxy‐4‐methyl‐2‐pyridone: two new pseudopolymorphs and two cocrystals with products of an in situ nucleophilic aromatic substitution

Four crystal structures of 3‐cyano‐6‐hydroxy‐4‐methyl‐2‐pyridone (CMP), viz. the dimethyl sulfoxide monosolvate, C₇H₆N₂O₂·C₂H₆OS, (1), the N,N‐dimethylacetamide monosolvate, C₇H₆N₂O₂·C₄H₉NO, (2), a cocrystal with 2‐amino‐4‐dimethylamino‐6‐methylpyrimidine (as the salt 2‐amino‐4‐dimethylamino‐6‐methylpyrimidin‐1‐ium 5‐cyano‐4‐methyl‐6‐oxo‐1,6‐dihydropyridin‐2‐olate), C₇H₁₃N₄⁺·C₇H₅N₂O₂⁻, (3), and a cocrystal with N,N‐dimethylacetamide and 4,6‐diamino‐2‐dimethylamino‐1,3,5‐triazine [as the solvated salt 2,6‐diamino‐4‐dimethylamino‐1,3,5‐triazin‐1‐ium 5‐cyano‐4‐methyl‐6‐oxo‐1,6‐dihydropyridin‐2‐olate–N,N‐dimethylacetamide (1/1)], C₅H₁₁N₆⁺·C₇H₅N₂O₂⁻·C₄H₉NO, (4), are reported. Solvates (1) and (2) both contain the hydroxy group in a para position with respect to the cyano group of CMP, acting as a hydrogen‐bond donor and leading to rather similar packing motifs. In cocrystals (3) and (4), hydrolysis of the solvent molecules occurs and an in situ nucleophilic aromatic substitution of a Cl atom with a dimethylamino group has taken place. Within all four structures, an R₂²(8) N—H...O hydrogen‐bonding pattern is observed, connecting the CMP molecules, but the pattern differs depending on which O atom participates in the motif, either the ortho or para O atom with respect to the cyano group. Solvents and coformers are attached to these arrangements via single‐point O—H...O interactions in (1) and (2) or by additional R₄⁴(16) hydrogen‐bonding patterns in (3) and (4). Since the in situ nucleophilic aromatic substitution of the coformers occurs, the possible Watson–Crick C–G base‐pair‐like arrangement is inhibited, yet the cyano group of the CMP molecules participates in hydrogen bonds with their coformers, influencing the crystal packing to form chains.     

Two lanthanum(III) complexes containing η2‐pyrazolate and η2‐1,2,4‐triazolate ligands: intramolecular C—H...N/O interactions and coordination geometries

The lanthanum(III) complexes tris(3,5‐diphenylpyrazolato‐κ²N,N′)tris(tetrahydrofuran‐κO)lanthanum(III) tetrahydrofuran monosolvate, [La(C₁₅H₁₁N₂)₃(C₄H₈O)₃]·C₄H₈O, (I), and tris(3,5‐diphenyl‐1,2,4‐triazolato‐κ²N¹,N²)tris(tetrahydrofuran‐κO)lanthanum(III), [La(C₁₄H₁₀N₃)₃(C₄H₈O)₃], (II), both contain La^III atoms coordinated by three heterocyclic ligands and three tetrahydrofuran ligands, but their coordination geometries differ. Complex (I) has a mer‐distorted octahedral geometry, while complex (II) has a fac‐distorted configuration. The difference in the coordination geometries and the existence of asymmetric La—N bonding in the two complexes is associated with intramolecular C—H...N/O interactions between the ligands.     

Covalent‐assisted supramolecular synthesis: the effect of hydrogen bonding in cocrystals of 4‐tert‐butylbenzoic acid with isoniazid and its derivatized forms

A series of cocrystals of isoniazid and four of its derivatives have been produced with the cocrystal former 4‐tert‐butylbenzoic acid via a one‐pot covalent and supramolecular synthesis, namely 4‐tert‐butylbenzoic acid–isoniazid, C₆H₇N₃O·C₁₁H₁₄O₂, 4‐tert‐butylbenzoic acid–N′‐(propan‐2‐ylidene)isonicotinohydrazide, C₉H₁₁N₃O·C₁₁H₁₄O₂, 4‐tert‐butylbenzoic acid–N′‐(butan‐2‐ylidene)isonicotinohydrazide, C₁₀H₁₃N₃O·C₁₁H₁₄O₂, 4‐tert‐butylbenzoic acid–N′‐(diphenylmethylidene)isonicotinohydrazide, C₁₉H₁₅N₃O·C₁₁H₁₄O₂, and 4‐tert‐butylbenzoic acid–N′‐(4‐hydroxy‐4‐methylpentan‐2‐ylidene)isonicotinohydrazide, C₁₂H₁₇N₃O₂·C₁₁H₁₄O₂. The co‐former falls under the classification of a `generally regarded as safe' compound. The four derivatizing ketones used are propan‐2‐one, butan‐2‐one, benzophenone and 3‐hydroxy‐3‐methylbutan‐2‐one. Hydrogen bonds involving the carboxylic acid occur consistently with the pyridine ring N atom of the isoniazid and all of its derivatives. The remaining hydrogen‐bonding sites on the isoniazid backbone vary based on the steric influences of the derivative group. These are contrasted in each of the molecular systems.     

Eight new crystal structures of 5‐(hydroxymethyl)uracil, 5‐carboxyuracil and 5‐carboxy‐2‐thiouracil: insights into the hydrogen‐bonded networks and the predominant conformations of the C5‐bound residues

In order to examine the preferred hydrogen‐bonding pattern of various uracil derivatives, namely 5‐(hydroxymethyl)uracil, 5‐carboxyuracil and 5‐carboxy‐2‐thiouracil, and for a conformational study, crystallization experiments yielded eight different structures: 5‐(hydroxymethyl)uracil, C₅H₆N₂O₃, (I), 5‐carboxyuracil–N,N‐dimethylformamide (1/1), C₅H₄N₂O₄·C₃H₇NO, (II), 5‐carboxyuracil–dimethyl sulfoxide (1/1), C₅H₄N₂O₄·C₂H₆OS, (III), 5‐carboxyuracil–N,N‐dimethylacetamide (1/1), C₅H₄N₂O₄·C₄H₉NO, (IV), 5‐carboxy‐2‐thiouracil–N,N‐dimethylformamide (1/1), C₅H₄N₂O₃S·C₃H₇NO, (V), 5‐carboxy‐2‐thiouracil–dimethyl sulfoxide (1/1), C₅H₄N₂O₃S·C₂H₆OS, (VI), 5‐carboxy‐2‐thiouracil–1,4‐dioxane (2/3), 2C₅H₄N₂O₃S·3C₆H₁₂O₃, (VII), and 5‐carboxy‐2‐thiouracil, C₁₀H₈N₄O₆S₂, (VIII). While the six solvated structures, i.e. (II)–(VII), contain intramolecular S(6) O—H…O hydrogen‐bond motifs between the carboxy and carbonyl groups, the usually favoured R₂²(8) pattern between two carboxy groups is formed in the solvent‐free structure, i.e. (VIII). Further R₂²(8) hydrogen‐bond motifs involving either two N—H…O or two N—H…S hydrogen bonds were observed in three crystal structures, namely (I), (IV) and (VIII). In all eight structures, the residue at the ring 5‐position shows a coplanar arrangement with respect to the pyrimidine ring which is in agreement with a search of the Cambridge Structural Database for six‐membered cyclic compounds containing a carboxy group. The search confirmed that coplanarity between the carboxy group and the cyclic residue is strongly favoured.     

Three new olanzapine structures: the acetic acid monosolvate,and the propan‐2‐ol and propan‐2‐one hemisolvate monohydrates

The crystal structures of three new solvates of olanzapine [systematic name: 2‐methyl‐4‐(4‐methylpiperazin‐1‐yl)‐10H‐thieno[2,3‐b][1,5]benzodiazepine], namely olanzapine acetic acid monosolvate, C₁₇H₂₀N₄S·C₂H₄O₂, (I), olanzapine propan‐2‐ol hemisolvate monohydrate, C₁₇H₂₀N₄S·0.5C₃H₈O·H₂O, (II), and olanzapine propan‐2‐one hemisolvate monohydrate, C₁₇H₂₀N₄S·0.5C₃H₆O·H₂O, (III), are presented and compared with other known olanzapine forms. There is a fairly close resemblance of the molecular conformation for all studied analogues. The crystal structures are built up through olanzapine dimers, which are characterized via C—H...π interactions between the aliphatic fragment (1‐methylpiperazin‐4‐yl) and the aromatic fragment (benzene system). All solvent (guest) molecules participate in hydrogen‐bonding networks. The crystal packing is sustained via intermolecular N_host—H...O_guest, O_guest—H...N_host, O_guest—H...O_guest and C_host—H...O_guest hydrogen bonds. It should be noted that the solvent propan‐2‐ol in (II) and propan‐2‐one in (III) show orientational disorder. The propan‐2‐ol molecule lies close to a twofold axis, while the propan‐2‐one molecule resides strictly on a twofold axis through the carbonyl C atom. In both cases, the water molecules present positional disorder of the H atoms.     

The preparation,characterization, structure and dissolution analysis of apremilast solvatomorphs

Apremilast (AP) {systematic name: (S )‐2‐[1‐(3‐ethoxy‐4‐methoxyphenyl)‐2‐(methylsulfonyl)ethyl]‐4‐acetamidoisoindoline‐1,3‐dione} is an inhibitor of phosphodieasterase‐4 (PDE4) and is indicated for the treatment of adult patients with active psoriatic arthritis. The ability of AP to form solvates has been investigated and three solvatomorphs of AP, namely, the AP ethyl acetate hemisolvate, C₂₂H₂₄N₂O₇S·0.5C₄H₈O₂, the AP toluene hemisolvate, C₂₂H₂₄N₂O₇S·0.5C₇H₈, and the AP dichloromethane monosolvate, C₂₂H₂₄N₂O₇S·CH₂Cl₂, were obtained. The three AP solvatomorphs were characterized by X‐ray powder diffraction, thermogravimetric analysis and differential scanning calorimetry. Single‐crystal X‐ray diffraction was used to analyze the structures, crystal symmetry, packing modes, stoichiometry and hydrogen‐bonding interactions of the solvatomorphs. In addition, dissolution analyses were performed to study the dissolution rates of different AP solvatomorph tablets in vitro and to make comparisons with commercial apremilast tablets (produced by Celgene); all three solvatomorphs showed similar dissolution rates and similar values of the similarity factor f₂ in a comparison of their dissolution profiles.     

Pyridine and 3‐methylpyridine solvates of the triple sulfa drug constitutent sulfamethazine

Sulfonamides display a wide variety of pharmacological activities. Sulfamethazine [abbreviated as SMZ; systematic name 4‐amino‐N‐(4,6‐dimethylpyrimidin‐2‐yl)benzenesulfonamide], one of the constitutents of the triple sulfa drugs, has wide clinical use. Pharmaceutical solvates are crystalline solids of active pharmaceutical ingredients (APIs) incorporating one or more solvent molecules in the crystal lattice, and these have received special attention, as the solvent molecule can impart characteristic physicochemical properties to APIs and solvates, therefore playing a significant role in drug development. The ability of SMZ to form solvates has been investigated. Both pyridine and 3‐methylpyridine form solvates with SMZ in 1:1 molar ratios. The pyridine monosolvate, C₁₂H₁₄N₄O₂S·C₅H₅N, crystallizes in the orthorhombic space group Pna 2₁, with Z = 8 and two molecules per assymetric unit, whereas the 3‐methylpyridine monosolvate, C₁₂H₁₄N₄O₂S·C₆H₇N, crystallizes in the orthorhombic space group P 2₁2₁2₁, with Z = 4. Crystal structure analysis reveals intramolecular N—H…N hydrogen bonds between the molecules of SMZ and the pyridine solvent molecules. The solvent molecules in both structures play an active part in strong intermolecular interactions, thereby contributing significantly to the stability of both structures. Three‐dimensional hydrogen‐bonding networks exist in both structures involving at least one sulfonyl O atom and the amine N atom. In the pyridine solvate, there is a short π–π interaction [centroid–centroid distance = 3.926 (3) Å] involving the centroids of the pyridine rings of two solvent molecules and a weak intermolecular C—H…π interaction also contributes to the stability of the crystal packing.     

Multicomponent pharmaceutical cocrystals: furosemide and pentoxifylline

The combination of the active pharmaceutical ingredients furosemide [4‐chloro‐2‐(furan‐2‐ylmethylamino)‐5‐sulfamoylbenzoic acid] and pentoxifylline [3,7‐dimethyl‐1‐(5‐oxohexyl)‐3,7‐dihydro‐1H‐purine‐2,6‐dione] produces a 1:1 cocrystal, C₁₂H₁₁ClN₂O₅S·C₁₃H₁₈N₄O₃, (I), a 1:1 cocrystal hydrate, C₁₂H₁₁ClN₂O₅S·C₁₃H₁₈N₄O₃·H₂O, (II), and a 1:1 cocrystal acetone solvate, C₁₂H₁₁ClN₂O₅S·C₁₃H₁₈N₄O₃·C₂H₆O, (III). These structures exhibit the presence of a rarely encountered synthon with the graph set R₂²(7). All potential hydrogen‐bond donors of furosemide participate in hydrogen‐bond formation in (I)–(III). However, only two hydrogen‐bond acceptors of furosemide are active in (I) and (II), and only one is active in (III). Four hydrogen‐bond acceptors of pentoxifylline are active in (II), three in (I) and two in (III). These observations are in good agreement with the calculated packing indexes of 69.5, 69.6 and 68.8% for (II), (I) and (III), respectively.     

Solvent‐mediated pseudo‐quadruple hydrogen‐bond motifs in three lamotrigine–carboxylic acid complexes

Lamotrigine, an antiepileptic drug, has been complexed with three aromatic carboxylic acids. All three compounds crystallize with the inclusion of N,N‐dimethylformamide (DMF) solvent, viz. lamotriginium [3,5‐diamino‐6‐(2,3‐dichlorophenyl)‐1,2,4‐triazin‐2‐ium] 4‐iodobenzoate N,N‐dimethylformamide monosolvate, C₉H₈Cl₂N₅⁺·C₇H₄IO₂⁻·C₃H₇NO, (I), lamotriginium 4‐methylbenzoate N,N‐dimethylformamide monosolvate, C₉H₇Cl₂N₅⁺·C₈H₈O₂⁻·C₃H₇NO, (II), and lamotriginium 3,5‐dinitro‐2‐hydroxybenzoate N,N‐dimethylformamide monosolvate, C₉H₈Cl₂N₅⁺·C₇H₃N₂O₇⁻·C₃H₇NO, (III). In all three structures, proton transfer takes place from the acid to the lamotrigine molecule. However, in (I) and (II), the acidic H atom is disordered over two sites and there is only partial transfer of the H atom from O to N. In (III), the corresponding H atom is ordered and complete proton transfer has occurred. Lamotrigine–lamotrigine, lamotrigine–acid and lamotrigine–solvent interactions are observed in all three structures and they thereby exhibit isostructurality. The DMF solvent extends the lamotrigine–lamotrigine dimers into a pseudo‐quadruple hydrogen‐bonding motif.     

Synthesis,crystal structures,photoluminescence, electrochemistry and DFT study of aluminium(III) and gallium(III) complexes containing a novel tetradentate Schiff base ligand

Single crystals of the aluminium and gallium complexes of 6,6′‐{(1E,1′E)‐[1,2‐phenylenebis(azanylylidene)]bis(methanylylidene)}bis(2‐methoxyphenol), namely diaqua(6,6′‐{(1E,1′E)‐[1,2‐phenylenebis(azanylylidene)]bis(methanylylidene)}bis(2‐methoxyphenolato)‐κ⁴O¹,N,N′,O^1′)aluminium(III) nitrate ethanol monosolvate, [Al(C₂₂H₁₈N₂O₄)(H₂O)₂]NO₃·C₂H₅OH, 1 , and diaqua(6,6′‐{(1E,1′E)‐[1,2‐phenylenebis(azanylylidene)]bis(methanylylidene)}bis(2‐methoxyphenolato)‐κ⁴O¹,N,N′,O^1′)gallium(III) nitrate ethanol monosolvate, [Ga(C₂₂H₁₈N₂O₄)(H₂O)₂]NO₃·C₂H₅OH, 2 , were obtained after successful synthesis in ethanol. Both complexes crystallized in the triclinic space group P, with two molecules in the asymmetric unit. In both structures, in one of the independent molecules the tetradentate ligand is almost planar while in the other independent molecule the ligand shows significant distortions from planarity, as illustrated by the largest distance from the plane constructed through the central metal atom and the O,N,N′,O′‐coordinating atoms of the ligand in 1 of 1.155 (3) Å and a distance of 1.1707 (3) Å in 2 . The possible reason for this is that there are various strong π‐interactions in the structures. This was confirmed by density functional theory (DFT) calculations, as were the other crystallographic data. DFT was also used to predict the outcome of cyclic voltammetry experiments. Ligand oxidation is more stabilized in the gallium complex. Solid‐state photoluminescence gave an 80 nm red‐shifted spectrum for the gallium complex, whereas the aluminium complex maintains the ligand curve with a smaller red shift of 40 nm.     

Two phosphonodehydrotripeptides: Boc0–Gly1–Δ(Z)Phe2–α‐Abu3PO3Me2 and Boc0–Gly1–Δ(Z)Phe2–α‐Nva3PO3Et2

The present paper reports the crystal structures of two short phosphonotripeptides (one in two crystal forms) containing one ΔPhe (dehydrophenylalanine) residue, namely dimethyl (3‐{[tert‐butoxycarbonylglycyl‐α,β‐(Z)‐dehydrophenylalanyl]amino}propyl)phosphonate, Boc⁰–Gly¹–Δ(Z)Phe²–α‐Abu³PO₃Me₂, C₂₁H₃₂N₃O₇P, (I), and diethyl (4‐{[tert‐butoxycarbonylglycyl‐α,β‐(Z)‐dehydrophenylalanyl]amino}butyl)phosphonate, Boc⁰–Gly¹–Δ(Z)Phe²–α‐Nva³PO₃Et₂, as the propan‐2‐ol monosolvate 0.122‐hydrate, C₂₄H₃₈N₃O₇P·C₃H₈O·0.122H₂O, (II), and the ethanol monosolvate 0.076‐hydrate, C₂₄H₃₈N₃O₇P·C₂H₆O·0.076H₂O, (III). The crystals of (II) and (III) are isomorphous but differ in the type of solvent. The phosphono group is linked directly to the last C_α atom in the main chain for all three peptides. All the amino acids are trans linked in the main chains. The crystal structures exhibit no intramolecular hydrogen bonds and are stabilized by intermolecular hydrogen bonds only.     

The heteroscorpionate ligand 2,2‐bis(3,5‐dimethylpyrazol‐1‐yl)‐1,1‐diphenylethanol and an easy preparation of its tungsten complex

The heteroscorpionate ligand 2,2‐bis(3,5‐dimethylpyrazol‐1‐yl)‐1,1‐diphenylethanol, C₂₄H₂₆N₄O, features in the solid state an intramolecular O—H…N hydrogen bond. A heteroscorpionate tungsten complex, cis‐[2,2‐bis(3,5‐dimethylpyrazolyl)‐1,1‐diphenylethanolato]chloridodioxidotungsten(VI) tetrahydrofuran monosolvate, [W(C₂₄H₂₅N₄O)ClO₂]·C₄H₈O, was prepared by the simple mixing of solutions of the ligand and WOCl₄ in tetrahydrofuran. The tungsten complex was isolated after standing for several weeks. The complex exhibits a κ³N,N′,O‐coordination of the ligand. This simple synthetic procedure allows access to the cis isomer in high yield without additional purification steps. The Hirshfeld surface analysis shows a change of the intermolecular contacts due to the coordination of the WO₂Cl unit with the ligand molecule.     

Polymorph VI of sulfapyridine: interpenetrating two‐ and three‐dimensional hydrogen‐bonded nets formed from two tautomeric forms

Polymorph VI of 4‐amino‐N‐(2‐pyridyl)benzenesulfonamide, C₁₁H₁₁N₃O₂S, is monoclinic (space group P2₁/n). The asymmetric unit contains two different tautomeric forms. The structure displays N—H...N and N—H...O hydrogen bonding. The two independent molecules form two separate two‐ and three‐dimensional hydrogen‐bonded networks which interpenetrate. The observed patterns of hydrogen bonding are analogous to those in polymorph I of sulfathiazole.     

6‐Propyl‐2‐thiouracil versus 6‐methoxymethyl‐2‐thiouracil: enhancing the hydrogen‐bonded synthon motif by replacement of a methylene group with an O atom

The understanding of intermolecular interactions is a key objective of crystal engineering in order to exploit the derived knowledge for the rational design of new molecular solids with tailored physical and chemical properties. The tools and theories of crystal engineering are indispensable for the rational design of (pharmaceutical) cocrystals. The results of cocrystallization experiments of the antithyroid drug 6‐propyl‐2‐thiouracil (PTU) with 2,4‐diaminopyrimidine (DAPY), and of 6‐methoxymethyl‐2‐thiouracil (MOMTU) with DAPY and 2,4,6‐triaminopyrimidine (TAPY), respectively, are reported. PTU and MOMTU show a high structural similarity and differ only in the replacement of a methylene group (–CH₂–) with an O atom in the side chain, thus introducing an additional hydrogen‐bond acceptor in MOMTU. Both molecules contain an ADA hydrogen‐bonding site (A = acceptor and D = donor), while the coformers DAPY and TAPY both show complementary DAD sites and therefore should be capable of forming a mixed ADA/DAD synthon with each other, i.e. N—H…O, N—H…N and N—H…S hydrogen bonds. The experiments yielded one solvated cocrystal salt of PTU with DAPY, four different solvates of MOMTU, one ionic cocrystal of MOMTU with DAPY and one cocrystal salt of MOMTU with TAPY, namely 2,4‐diaminopyrimidinium 6‐propyl‐2‐thiouracilate–2,4‐diaminopyrimidine–N,N‐dimethylacetamide–water (1/1/1/1) (the systematic name for 6‐propyl‐2‐thiouracilate is 6‐oxo‐4‐propyl‐2‐sulfanylidene‐1,2,3,6‐tetrahydropyrimidin‐1‐ide), C₄H₇N₄⁺·C₇H₉N₂OS⁻·C₄H₆N₄·C₄H₉NO·H₂O, (I), 6‐methoxymethyl‐2‐thiouracil–N,N‐dimethylformamide (1/1), C₆H₈N₂O₂S·C₃H₇NO, (II), 6‐methoxymethyl‐2‐thiouracil–N,N‐dimethylacetamide (1/1), C₆H₈N₂O₂S·C₄H₉NO, (III), 6‐methoxymethyl‐2‐thiouracil–dimethyl sulfoxide (1/1), C₆H₈N₂O₂S·C₂H₆OS, (IV), 6‐methoxymethyl‐2‐thiouracil–1‐methylpyrrolidin‐2‐one (1/1), C₆H₈N₂O₂S·C₅H₉NO, (V), 2,4‐diaminopyrimidinium 6‐methoxymethyl‐2‐thiouracilate (the systematic name for 6‐methoxymethyl‐2‐thiouracilate is 4‐methoxymethyl‐6‐oxo‐2‐sulfanylidene‐1,2,3,6‐tetrahydropyrimidin‐1‐ide), C₄H₇N₄⁺·C₆H₇N₂O₂S⁻, (VI), and 2,4,6‐triaminopyrimidinium 6‐methoxymethyl‐2‐thiouracilate–6‐methoxymethyl‐2‐thiouracil (1/1), C₄H₈N₅⁺·C₆H₇N₂O₂S⁻·C₆H₈N₂O₂S, (VII). Whereas in (I) only an AA/DD hydrogen‐bonding interaction was formed, the structures of (VI) and (VII) both display the desired ADA/DAD synthon. Conformational studies on the side chains of PTU and MOMTU also revealed a significant deviation for cocrystals (VI) and (VII), leading to the desired enhancement of the hydrogen‐bond pattern within the crystal.     

Brucinium 3,5‐dinitro­benzoate methanol solvate,methanol disolvate and trihydrate

Crystals of brucinium 3,5‐dinitro­benzoate methanol solvate, C₂₃H₂₇N₂O₄⁺·C₇H₃N₂O₆⁻·CH₃OH, (I), brucinium 3,5‐dinitro­benzoate methanol disolvate, C₂₃H₂₇N₂O₄⁺·C₇H₃N₂O₆⁻·2CH₃OH, (II), and brucinium 3,5‐dinitro­benzoate trihydrate, C₂₃H₂₇N₂O₄⁺·C₇H₃N₂O₆⁻·3H₂O, (III), were obtained from methanol [for (I) and (II)] or ethanol solutions [for (III)]. The brucinium cations and 3,5‐dinitro­benzoate anions are linked by ionic N—H⁺⋯O⁻ hydrogen bonds. In the crystals of (I), (II) and (III), the brucinium cations exhibit different modes of packing, viz. corrugated ribbons, pillars and corrugated monolayer sheets, respectively. While in (III), the amide O atom of the brucinium cation participates in O—H⋯O hydrogen bonds, in which water mol­ecules are the donors, in (I) and (II), the amide O atom of the brucinium cation is involved in weak C—H⋯O hydrogen bonds and other brucinium cations are the donors.     

Similar sulfonamides with different crystal structures: sulfasymazine and sulfatriazine

The crystal structures of 4‐amino‐N‐(4,6‐diethyl‐1,3,5‐triazin‐2‐yl)benzenesulfonamide, C₁₃H₁₇N₅O₂S, and 4‐amino‐N‐(4,6‐dimethoxy‐1,3,5‐triazin‐2‐yl)benzenesulfonamide, C₁₁H₁₃N₅O₄S, also known as sulfasymazine and sulfatriazine, respectively, are dominated by hydrogen‐bond interactions. All three potential hydrogen‐bond donors are employed in each case, resulting in a three‐dimensional network for sulfasymazine, while an entirely different hydrogen‐bonded layer structure is obtained for sulfatriazine. This study demonstrates the versatile nature of the hydrogen‐bonding capabilities in sulfonamides, even in structurally very similar molecules.     

Hydrogen‐bonded supramolecular motifs in 2‐amino‐4,6‐dimethoxypyrimidinium picrate and pyrimethaminium picrate dimethyl sulfoxide solvate

In the crystal structures of 2‐amino‐4,6‐dimethoxypyrimidinium 2,4,6‐trinitrophenolate (picrate), C₆H₁₀N₃O₂⁺·C₆H₂N₃O₇⁻, (I), and 2,4‐diamino‐5‐(4‐chlorophenyl)‐6‐ethylpyrimidin‐1‐ium (pyrimethaminium or PMN) picrate dimethyl sulfoxide solvate, C₁₂H₁₄ClN₄⁺·C₆H₂N₃O₇⁻·C₂H₆OS, (II), the 2‐amino‐4,6‐dimethoxypyrimidine and PMN cations are protonated at one of the pyrimidine N atoms. The picrate anion interacts with the protonated cations through bifurcated N—H...O hydrogen bonds, forming R₂¹(6) and R₁²(6) ring motifs. In (I), Z′ = 2. In (II), two inversion‐related PMN cations are connected through a pair of N—H...N hydrogen bonds involving the 4‐amino group and the uncharged N atom of the pyrimidine ring, forming a cyclic hydrogen‐bonded R₂²(8) motif. In addition to the pairing, the O atom of the dimethyl sulfoxide solvent molecule bridges the 2‐amino and 4‐amino groups on both sides of the paired bases, resulting in a self‐complementary …DADA… array of quadruple hydrogen‐bonding patterns.     

Three new quinuclidine‐based structures: second harmonic generation response for 1,2‐bis(1‐azoniabicyclo[2.2.2]octan‐3‐ylidene)hydrazine dichloride

The crystal structures of three quinuclidine‐based compounds, namely (1‐azabicyclo[2.2.2]octan‐3‐ylidene)hydrazine monohydrate, C₇H₁₃N₃·H₂O ( 1 ), 1,2‐bis(1‐azabicyclo[2.2.2]octan‐3‐ylidene)hydrazine, C₁₄H₂₂N₄ ( 2 ), and 1,2‐bis(1‐azoniabicyclo[2.2.2]octan‐3‐ylidene)hydrazine dichloride, C₁₄H₂₄N₄²⁺·2Cl^? ( 3 ), are reported. In the crystal structure of 1 , the quinuclidine‐substituted hydrazine and water molecules are linked through N—H…O and O—H…N hydrogen bonds, forming a two‐dimensional array. The compound crystallizes in the centrosymmetric space group P2₁/c. Compound 2 was refined in the space group Pccn and exhibits no hydrogen bonding. However, its hydrochloride form 3 crystallizes in the noncentrosymmetric space group Pc. It shows a three‐dimensional network structure via intermolecular hydrogen bonding (N—H…C and N/C—H…Cl). Compound 3 , with its acentric structure, shows strong second harmonic activity.